Could ALLO-715 Compete or Complement Carvykti / Abecma? ASH 2021 Day 3 Allogene Investor Event

On Monday, December 13, Allogene held their ASH 2021 investor event (presentation) providing updated clinical results from their BCMA (ALLO-715) and CD19 (ALLO-501 and ALLO-501A) allogeneic CAR-T programs. Bellow, Celltelligence provides insights on how ALLO-715 may be able to compete with autologous BCMA CAR-Ts.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.